Preparation, Characterization and In Vitro Evaluation of Nanosuspension for the Treatment of Schizophrenia

Abstract

The current study aims to construct a perphenazine oral nanosuspension utilizing the solvent evaporation technique with a variety of stabilizers and surfactants, including PVPK30, Pluronic F127, urea, and SLS. In order to obtain desired size and saturation solubility, several as well as process factors were tuned. Particle size, zeta potential, saturation solubility, dissolving rate, morphological study (SEM), and in-vitro dissolution study were all used to characterize the produced Nanosuspension. The improved formulation's (F12) zeta potential value was discovered to be -7mv, which was determined to be within acceptable bounds. It was discovered that the average particle size of optimal formulations (F12) in nanosuspension was 118 nm. According to the in vitro investigations, formulation F12 exhibits the greatest 98.65% of the medication is released within 30 minutes. The drug was not released for minutes by any of the other formulations. Understanding how the release of drugs via Nanosuspension functioned was aided by the application of mathematical formulae that included zero out, and first out, method equation. R2 analysis revealed that the enhanced 1st order kinetics by F12. Keywords: Perphenazine, PVPK-30, Poloxamer 184, Pluronic F127, Urea, SLS.